Mirum Pharmaceuticals, Inc. (MIRM)
| Market Cap | 532.63M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -132.49M |
| Shares Out | 30.45M |
| EPS (ttm) | -9.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $17.45 |
| Previous Close | $17.49 |
| Change ($) | -0.04 |
| Change (%) | -0.23% |
| Day's Open | 17.65 |
| Day's Range | 17.01 - 17.91 |
| Day's Volume | 69,816 |
| 52-Week Range | 14.94 - 27.43 |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -150.75% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
FOSTER CITY, Calif. & BEIJING--(BUSINESS WIRE)--CANbridge and Mirum Enter into Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in Greater China.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif. & PARIS--(BUSINESS WIRE)--Mirum and Vivet Enter into Exclusive Worldwide Option and License Agreement for Gene Therapy Programs Targeting PFIC
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -150.88% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for ...
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates
Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients with Primary Sclerosing Cholangitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides Corporate Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021
Mirum Pharmaceuticals (MIRM) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Oberland Capital Announce Up to $210 Million Funding Arrangement
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Virtual Investor Day 2020
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #AASLD--Mirum Data Presented at AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with ALGS Treated with Maralixibat
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Presents New Data From its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Broadens Expanded Access Program for Maralixibat in Alagille Syndrome to Europe and Australia
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the AASLD Annual Meeting
MoA reduces bile acid systemic levels. Potential utility across wide range of rare liver diseases.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the NASPGHAN Annual Meeting 2020
FOSTER CITY, Calif., Oct. 15, 2020 /PRNewswire/ -- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilit...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Investor Conferences in September
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum initiates rolling NDA submission for maralixibat for the treatment of cholestatic pruritus in patients with ALGS & launches EAP
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients with PFIC2 at Digital International Liver Congress
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates
Mirum Pharmaceuticals: Undervalued Rare Disease Player With Clear Path To Market
It appears the FDA is willing to work with Mirium to get maralixibat approved as quickly as possible.
Mirium Pharmaceuticals Inc. (NASDAQ:MIRM) shares continue to soar, having nearly tripled since mid-December after it had a successful pre-New Drug Application meeting with the Food and Drug Administrati...
This newly public drug developer tripled its stock price in November following positive FDA news.
The company's clinical trial is taking an important step forward.
Mirum Pharmaceuticals And Maralixibat In Alagille Syndrome
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) recently went public, offering 5 million shares at $15 each.
Mirum Pharmaceuticals (NASDAQ: MIRM) made its public debut Thursday morning, opening at $13 after being priced at $15 per share.
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and p... [Read more...]
| Industry Biotechnology | IPO Date Jul 18, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol MIRM |
Analyst Forecasts
According to 7 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price forecast is 50.29, which is an increase of 188.19% from the latest price.